Project Grant C06OD034040
- This $150,607 National Science Foundation project grant will support a research community development project focused on collaborative research related to knowledge of HIV/AIDS. Led by the University of Washington with a completion date of August 2026, the project aims to bring together social scientific and humanistic scholars within the interdisciplinary field of science and technology studies. Key activities over the three-year period will include organizing three annual workshops around...
- Federal Grant Award Summary Howard Brown Health Center received a $300,000 Project Grant award from the HIV/AIDS Bureau under the HIV-Related Training and Technical Assistance program (CFDA 93.145), effective September 1, 2025 through August 31, 2026. The Chicago-based Federally Qualified Health Center (FQHC) will implement the FY 2025 Ryan White HIV/AIDS Program (RWHAP) Part C Capacity Development Program, with a specific focus on HIV Care Innovation through streamlining eligibility...
- Federal Project Grant Award Summary George Washington University received a $731,738 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded September 10, 2025, with a completion date of September 9, 2028. The award supports a pilot feasibility study to integrate Pre-Exposure Prophylaxis (PrEP) into emergency departments (ED) and urgent care (UC) settings using evidence-based decision support tools (DST). The...
- Grant Award Summary The University of Washington received a $4.665 million Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded June 15, 2025, with completion scheduled for May 31, 2029. This project, titled "Transforming Systems of Care to Address HIV, HIV Risk, and Substance Use Disorders in Prisons," will develop and implement a novel prison learning health system model embedded across Washington's 11...
- Federal Project Grant Award Summary Boston Medical Center Corporation received a $711,993 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 11, 2025, with completion targeted for May 31, 2026. This award funds investigator-initiated biomedical research examining the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 (Human Immunodeficiency Virus) pathogenesis,...
- Federal Project Grant Award Summary The University of Washington received a $985,308 project grant from the National Institute of Child Health and Human Development under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective September 1, 2025 through May 31, 2030. This research initiative, titled "Advancing Pharmacy-Based Delivery of Primary STI and HIV Prevention for Cisgender Women," will develop and evaluate innovative pharmacy-based...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $381,487 to the University of Maryland, Baltimore (UMB) to assess the early implementation of long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) among adolescent girls and young women (AGYW) at high risk of HIV acquisition in Zambia. The key objectives are to: 1) Evaluate implementation determinants of CAB-LA...
- Federal Project Grant Award Summary Fred Hutchinson Cancer Center received a $500,000 project grant awarded September 12, 2025, under the Trans-NIH Research Support program (CFDA 93.310) from the Office of the Director to conduct a hybrid effectiveness-implementation cluster-randomized controlled trial evaluating telehealth-optimized delivery of HIV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) at community pharmacies in western Kenya. The research deliverables include...
- This Project Grant award in the amount of $431,712, funded by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve HIV testing among children under five in rural Uganda. The primary goal is to engage with traditional healers to facilitate HIV counseling and testing via oral swab antigen tests for this vulnerable pediatric population. The award supports two key activities: 1) determining barriers and...
- Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Vanderbilt University Medical Center a $859,083 Project Grant on August 21, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support the Southeastern HIV Implementation Science Hub through July 31, 2030. This initiative, developed in partnership with Emory Center for AIDS Research and Tennessee Center for AIDS Research, delivers implementation science (IS) technical consultation and...
DEVELOPING A COMMUNITY-BASED FACILITY TO SUPPORT NEXT GENERATION BIOMEDICAL HIV RESEARCH - PROJECT SUMMARY/ABSTRACT WARDS 7 AND 8 IN WASHINGTON, DC ARE HOME TO SOME OF THE NATION'S MOST STARK RACIAL INEQUITIES IN HEALTH AND SOCIOECONOMIC INDICATORS, WITH RESIDENTS OF THESE WARDS BEING UNDERSERVED IN HEALTHCARE AND UNDERREPRESENTED PUBLIC HEALTH RESEARCH. AMONG THESE HEALTH INEQUITIES IS A SIGNIFICANTLY HIGHER BURDEN OF HIV, YET NONE OF THE MAJOR HIV-RELATED RESEARCH FACILITIES IN DC ARE LOCATED WITHIN THESE WARDS. TWO CENTRAL HUBS FOR HIV RESEARCH WITHIN DC-THE DC CENTER FOR AIDS RESEARCH AND THE DC CLINICAL TRIALS UNIT-BOTH OPERATE PRIMARILY OUT OF FACILITIES IN WARD 2, AND THE EFFICACY OF THIS RESEARCH WOULD BE ENHANCED BY STRONGER REPRESENTATION OF MARGINALIZED COMMUNITIES IN PROTOCOLS TO OPTIMIZE THE IMPACT OF THIS WORK ON THE NEIGHBORHOODS IN DC THAT ARE THE HARDEST HIT BY HIV, ITS CO-MORBIDITIES/CO-INFECTIONS, AND OTHER CO-OCCURRING HEALTH INEQUITIES. THUS, THE GOAL OF THE PROPOSED HIV RESEARCH FACILITIES AWARD IS TO FUND THE BUILD-OUT OF A NEW STATE-OF-THE-ART, COMMUNITY-CENTERED CLINICAL AND TRANSLATIONAL HIV RESEARCH FACILITY LOCATED WITHIN THE NEW FLAGSHIP WHITMAN-WALKER BUILDING CURRENTLY BEING CONSTRUCTED IN DC'S WARD 8, TO BE USED JOINTLY BY HIV INVESTIGATORS AT BOTH WHITMAN-WALKER AND GEORGE WASHINGTON UNIVERSITY (GWU). THE PROPOSED FACILITY WOULD ADD 10,300 SQUARE FEET OF DEDICATED RESEARCH SPACE, INCLUDING A STATE-OF-THE-ART RESEARCH LAB AND A RESEARCH PHARMACY WITH CAPACITY FOR STERILE COMPOUNDING OF INVESTIGATIONAL PRODUCTS, MORE THAN DOUBLING THE AVAILABLE SPACE FOR RESEARCH IN THIS BUILDING AND SERVING AS THE PRIMARY COLLABORATIVE HUB FOR HIV-FOCUSED RESEARCH IN SOUTHEAST DC. DOING SO WILL SIGNIFICANTLY: (1) INCREASE THE OVERALL VOLUME OF RESEARCH ABLE TO BE CONDUCTED; (2) ENHANCE THE COLLABORATION OF WHITMAN-WALKER AND GWU INVESTIGATORS, BOLSTERING THE STRATEGIC INTEGRATION OF BOTH RESEARCH PROGRAMS; (3) EXPAND THE SCOPE AND TECHNICAL CAPABILITIES OF THE WORK THAT IS POSSIBLE NOT ONLY FOR BOTH INSTITUTIONS BUT ALSO WITHIN THESE SPECIFIC NEIGHBORHOODS OF DC; (4) INDIRECTLY EXPAND THE AVAILABLE SPACE FOR SOCIAL/BEHAVIORAL AND PUBLIC HEALTH RESEARCH AS WELL BY RELOCATING ALL CLINICAL AND TRANSLATIONAL RESEARCH TO THE NEW FACILITY; (5) PROVIDE LOCAL COMMUNITIES WITH GREATER ACCESS TO AND REPRESENTATION IN CUTTING- EDGE HIV SCIENCE AND NEW OPPORTUNITIES TO HELP INFORM THESE COLLABORATIVE RESEARCH AGENDAS; (6) FACILITATE GREATER TRANSLATION AND DISSEMINATION OF BREAKTHROUGHS IN HIV SCIENCE WITHIN LOCAL AND NATIONAL POLICY CONTEXTS THAT WILL BENEFIT BOTH LOCAL DC COMMUNITIES AND COMMUNITIES ACROSS THE COUNTRY; AND (7) PROMOTE NEW OPPORTUNITIES FOR TRAINING AND MENTORSHIP. IN SUM, THE PROPOSED PROJECT WILL HAVE A MULTIPLICATIVE IMPACT ON BOTH LOCAL AND NATIONAL HIV RESEARCH THROUGH THIS UNIQUE PLAN TO INCREASE THE SIZE AND SCOPE OF FACILITIES AVAILABLE AND CO-LOCATE TWO OF DC'S TOP HIV RESEARCH INSTITUTIONS TO LEVERAGE EXISTING PARTNERSHIPS AND FORGE NEW, COMMUNITY-CENTERED COLLABORATIVE RESEARCH AGENDAS. IN DOING SO, THE AWARD WILL BRING CUTTING-EDGE BREAKTHROUGHS IN HIV TREATMENT AND PREVENTION SCIENCE DIRECTLY TO UNDERSERVED COMMUNITIES MOST IMPACTED BY THE HIV EPIDEMIC IN DC AND HAS SIGNIFICANT POTENTIAL FOR PUBLIC HEALTH IMPACT FOR DECADES TO COME.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/20/26 | ||
| Not listed | $0 | 8/11/25 | ||
| Not listed | $0 | 8/11/25 | ||
| Not listed | $0 | 3/22/25 | ||
| Not listed | $0 | 3/22/25 |